Previous 10 | Next 10 |
Accolade, Inc. (ACCD) Q1 2022 Earnings Conference Call July 08, 2021, 04:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medical Officer Conference Call Participants David Grossman - Stifel Michael Cherny - Bank of America Ric...
Image source: The Motley Fool. Accolade, Inc. (NASDAQ: ACCD) Q1 2022 Earnings Call Jul 08, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Accolade, Inc. (ACCD) Q1 2022 Earnings Call Transcript
Accolade (ACCD): Q1 GAAP EPS of -$0.84 misses by $0.47.Revenue of $59.5M (+65.7% Y/Y) beats by $3.72M.Press Release For further details see: Accolade EPS misses by $0.47, beats on revenue
Fiscal first quarter 2022 revenue of $59.5 million, a 66% increase compared to fiscal first quarter 2021 revenue of $35.9 million Company raises guidance for fiscal year 2022 to $300 million - $305 million, a 78% increase at the midpoint compared to fiscal year 2021 revenue of $17...
SEATTLE, June 17, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced that it will release fiscal first quarter 2022 financial results on Thursday, July 8, 2021, after the market close...
Accolade to begin offering virtual primary care and mental health consultations directly to members. $200bn+ combined total addressable market materially expands opportunity to reinvent healthcare with a focus on improving health outcomes and managing rising costs. Combi...
Betsy Nabel and Jeff Brodsky join Accolade Board of Directors New board directors bring expertise in healthcare services, policy, and human resources PR Newswire SEATTLE , June 3, 2021 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company reinventing healthcar...
This technology-focused healthcare infrastructure platform connects payors, providers, and employers in an efficient and analytical way. As a new growth-based company seeing 40% CAGR revenues over the past two years, net income remains negative but profitability is higher than their p...
Gainers: [[VRNA]] +31.8%. [[PDD]] +6.1%. [[SHYF]] +4.6%. [[OCX]] +3.9%. [[VERI]] +3.9%.Losers: [[IOVA]] -11.1%. [[PRPL]] -4.0%. [[PRVB]] -3.4%. [[OZON]] -3.3%. [[ACCD]] -3.0%. For further details see: VRNA, PDD, IOVA and PRVB among after-hours movers
Accolade, Inc. (ACCD) Q4 2021 Results Conference Call May 05, 2021 04:30 PM ET Company Participants Todd Friedman - Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Conference Call Participants Michael Cher...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...